Spatiotemporally controlled co-Delivery of anti-Vasculature agent and cytotoxic drug by octreotide-Modified stealth liposomes

Pharmaceutical Research

Volumn 29, Issue 10, 2012, Pages 2902-2911

  Dai, Wenbing ^a,b   Jin, Wu ^a   Zhang, Junlin ^a   Wang, Xueqing ^a   Wang, Jiancheng ^a   Zhang, Xuan ^a   Wan, You ^b   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Neuroscience Research Institute   (China)

Author keywords

Combretastatin A 4; Doxorubicin; Octreotide; Programmed release; Spatiotemporally controlled co Delivery; Targeted delivery

Indexed keywords

COMBRETASTATIN A4; DOXORUBICIN; LIPOSOME; OCTREOTIDE; SOMATOSTATIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL TRANSPORT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG RECEPTOR BINDING; DRUG RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; LIGANDS; LIPOSOMES; MALE; MCF-7 CELLS; MICE; MICE, NUDE; OCTREOTIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SOMATOSTATIN; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866728365     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0797-2     Document Type: Article

References (36)

1. Lisa BP, James OB. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004;56:1649-59.
2. Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, Jon S, Langer RS, Farokhzad OC. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem Med Chem. 2007;2:1268-71.
3. Mitragotris S. Synergistic effect of enhancers for transdermal drug delivery. Pharm Res. 2000;17:1354-59.
4. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 2002;29:15-8.
5. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment ofmalignant disease. Cancer. 2004;100:2491-97.
6. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10:415-27.
7. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid. 2002;12:1063-70.
8. Nelkin BD, Ball DW. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep. 2001;8:157-60.
9. Yeung SC, She M, Yang H, Pan J, Sun L, Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab. 2007;92:2902-09.
10. Verheul HMW, Voest EE, Schlingemann RO. Are tumours angiogenesis-depent? J Pathol. 2004;202:5-13.
11. Lee SM, Woll PJ, Rudd R, Ferry D, O'Brien M, Middleton G, Spiro S, James L, Ali K, Jitlal M, Hackshaw A. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst. 2009;101:1049-57.
12. Sapra P, Tyagi P, Allen TM. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005;2:368-81.
13. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless J. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31:1133-40.
14. Reubi JC, Kvols L, Krenning E, Lamberts SW. Distribution of somatotatin receptors in normal and tumor tissue. Metabolism. 1990;39:78-81.
15. Volante M, Rosas R, Allia E, Granata R, Baragli A, Muccioli G, Papotti M. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol. 2008;286:219-29.
16. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, De Jong M, Wenger S, Reubi JC. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30: 1338-47.
17. Ginj M, Schmitt JS, Chen J, Waser B, Reubi JC, de Jong M, Schulz S, Maecke HR. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol. 2006;13:1081-90.
18. Shen H, Hu D, Du J, Wang X, Liu Y, Wang Y, Wei JM, Ma D, Wang P, Li L. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice. Eur J Pharmacol. 2008;601:23-9.
19. Lasfer M, Vadrot N, Schally AV, Nagy A, Halmos G, Pessayre D, Feldmann G, Reyl-Desmars FJ. Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238. J Hepatol. 2005;42:230-37.
20. Moody TW, Fuselier J, Coy DH, Mantey S, Pradhan T, Nakagawa T, Jensen RT. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells. Peptides. 2005;26:1560-66.
21. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies. Eur J Pharm Biopharm. 2010;74:467-73.
22. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, Sasisekharan R. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature. 2005;436:568-72.
23. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1:1112-16.
24. Zhang J, Jin W, Wang X, Wang J, Zhang X, Zhang Q. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharm. 2010;7:1159-68.
25. Zhang Y, Wang X, Wang J, Zhang X, Zhang Q. Octreotidemodified polymeric micelles as potential carriers for targeted docetaxel delivery to somatostatin receptor overexpressing tumor cells. Pharm Res. 2011;28:1167-78.
26. Sun M, Wang Y, Shen J, Xiao Y, Su Z, Ping Q. Octreotidemodification enhances the delivery and targeting of doxorubicinloaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Nanotechnology. 2010;21:475101-12.
27. Fritze A, Hens F, Kimpfler A, Schubert R, Peschka-Süss R. Remote loading of doxorubicin into nanoliposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta. 2006;1758:1633-40.
28. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA. 2008;105:2586-91.
29. Cairo CW, Gestwicki JE, Kanai M, Kiessling LL. Control of multivalent interactions by binding epitope density. J Am Chem Soc. 2002;124:1615-19.
30. Jule E, Nagasaki Y, Kataoka K. Lactose-installed poly(ethylene glycol)-poly(d, l-lactide) block copolymermicelles exhibit fast-rate binding and high affinity toward a protein bed simulating a cell surface. A surface plasmon resonance study. Bioconjug Chem. 2003;14:177-86.
31. Emanuel N, Kedar E, Bolotin E, Smorodinsky NI, Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Pharm Res. 1996;13:861-68.
32. Turka MJ, Watersb DJ, Low PS. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett. 2004;213:165-72.
33. Linuma H, Maruyama K, Okinaga K. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposomes on peritoneal dissemination of gastric cancer. Int J Cancer. 2002;299:130-37.
34. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine. Cancer Lett. 1990;53(2-3):183-90.
35. Lu WL, Qi XR, Zhang Q, Li RY, Wang GL, Zhang RJ, Wei SL. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J Pharmacol Sci. 2004;95(3):381-9.
36. Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19(4):424-36.